Compare TARA & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | ZSQR |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 204.6M |
| IPO Year | 2014 | 2020 |
| Metric | TARA | ZSQR |
|---|---|---|
| Price | $2.76 | $3.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $25.71 | N/A |
| AVG Volume (30 Days) | ★ 740.0K | 375.9K |
| Earning Date | 11-09-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.25 | ★ 50.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | $1,363,045.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $2.11 |
| 52 Week High | $7.82 | $16.62 |
| Indicator | TARA | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 58.36 |
| Support Level | N/A | $2.81 |
| Resistance Level | $4.13 | $4.64 |
| Average True Range (ATR) | 0.22 | 0.47 |
| MACD | -0.06 | 0.26 |
| Stochastic Oscillator | 8.21 | 79.36 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.